Anti-Rat DDR1/CD167a Rabbit Recombinant Antibody Proteintech 98629-1-RR

$299.00
In stock
SKU
98629-1-RR

 

DDR1, CAK, CD167 antigen-like family member A, CD1671, CD167a

Formulation::PBS, Azide Formulation::PBS, Azide1
Applications:Flow Cytometry (FC) Formulation::PBS, Azide2
 Reactivity:Rabbit / IgG Formulation::PBS, Azide3
Type:CatNo: Eg3226 Product name: Recombinant Rat DDR1 protein (rFc Tag) Source: mammalian cells-derived, pHZ-KIsec-C-rFc Tag: C-rFc Domain: 22-413 aa of NM_001166022.1 Sequence: DMKGHFDPAKCRYALGMQDRTIPDSDISVSSSWSDSTAARHSRLESSDGDGAWCPAGPVFPKEEEYLQVDLRRLHLVALVGTQGRHAGGLGKEFSRSYRLRYSRDGRRWMDWKDRWGQEVISGNEDPGGVVLKDLGPPMVARLVRFYPRADRVMSVCLRVELYGCLWRDGLLSYTAPVGQTMQLSEMVYLNDSTYDGYTAGGLQYGGLGQLADGVVGLDDFRQSQELRVWPGYDYVGWSNHSFPSGYVEMEFEFDRLRSFQTMQVHCNNMHTLGARLPGGVECRFKRGPAMAWEGEPVRHALGGSLGDPRARAISVPLGGHVGRFLQCRFLFAGPWLLFSEISFISDVVNDSSDTFPPAPWWPPGPPPTNFSSLELEPRGQQPVAKAEGSPT Predict reactive species Formulation::PBS, Azide4
RRID:25678 Formulation::PBS, Azide5
Storage Buffer:Q6MG19 Formulation::PBS, Azide6
Background Information:DDR1, or CD167a, is a member of the receptor tyrosine kinase (RTK) family, which plays a significant role in various cellular processes including cell proliferation, adhesion, migration, and extracellular matrix (ECM) remodeling. DDR1 is known for its unique discoidin domain that allows it to bind specifically to certain collagens, initiating downstream signaling pathways that can lead to cell transformation and tumor progression. Abnormal activation of DDR1 is closely associated with the development of various solid tumors, and it has been shown that DDR1 can prevent immune cells from infiltrating triple-negative breast cancer (TNBC) and eliminate tumor cells. Formulation::PBS, Azide7
biogegep8 Formulation::PBS, Azide8
biogegep9 Formulation::PBS, Azide9
Formulation::PBS, Azide0 Applications:Flow Cytometry (FC)0

 

 

Reviews

Write Your Own Review
You're reviewing:Anti-Rat DDR1/CD167a Rabbit Recombinant Antibody Proteintech 98629-1-RR
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.